Last updated: 2026-09-09 10:37:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Castle Biosciences, Inc. (CSTL) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $32,75, with a market capitalization of $1,01B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17,72 to $44,28. This page covers its latest market performance, valuation, price trends and company information.
$1,01B | |
$32,57 | |
$107,69 | |
$2,26 | |
$32,91 | |
165,15K | |
394,39K | |
-- | |
$44,28 | |
$17,72 | |
-- | |
-- |
Castle Biosciences, Inc. (CSTL) is trading at $31,83 in pre-market trading as of 2026-09-08 23:31:00, down 3,28% ($1,08) from the previous close of $32,91
Pre-market trading shows how investors are pricing CSTL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Castle Biosciences, Inc. (CSTL) moved from $33,50 to $32,75, representing a decline of 2,24% ($0,75).
The stock traded between $31,99 and $34,73 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 271,40 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 56,6%
CSTL is currently trading at $32,75, placing it 56,6% of the way from its 52-week low of $17,72 to its 52-week high of $44,28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 1002 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Castle Biosciences, Inc. (CSTL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.